INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS

The invention relates to inhibiting the development of hepatic fibrosis in a human subject afflicted with Non-Alcoholic Fatty Liver Disease and having a fibrosis score of zero comprising administering to the subject greater that 300 mg per day of 3β-arachidylamido-7α, 12α-dihydroxy-5β-cholan-24-oic...

Full description

Saved in:
Bibliographic Details
Main Authors GORFINE, Tali, BAHARAFF, Allen, HAYARDENY-NISSIMOIV, Liat, MATO DE LA PAZ, Jose, M
Format Patent
LanguageEnglish
French
German
Published 05.04.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to inhibiting the development of hepatic fibrosis in a human subject afflicted with Non-Alcoholic Fatty Liver Disease and having a fibrosis score of zero comprising administering to the subject greater that 300 mg per day of 3β-arachidylamido-7α, 12α-dihydroxy-5β-cholan-24-oic acid (Aramchol), or a pharmaceutically acceptable salt thereof, thereby inhibiting the development of hepatic fibrosis in said subject.
Bibliography:Application Number: EP20170835491